Timeframe
2018-2019
Funding
Janssen New Zealand
COMPASS staff
Barry Milne
Doney Zhang
Martin von Randow
Collaborators
Health Outcomes Associates
Richard Milne
Myeloma New Zealand
Ken Romeril
Description
This study was initiated by Myeloma New Zealand as the first international burden of illness study to be conducted on nationwide data. The aim was to produce the first report of the annual burden of myeloma in New Zealand, in terms of both the human and economic costs. Myeloma is a blood cancer that starts in bone marrow and can be found throughout the body. There are around 400 new cases in New Zealand each year, and management typically involves medication, chemotherapy, and for younger patients, bone marrow transplants.